Incannex Healthcare Ltd
IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide
Obstructive Sleep Apnea (OSA)
Countdown
297days
Phase 2 readout · ~ Apr 30, 2027 estimated
What's at stake
Phase 2 trial results for IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide in Obstructive Sleep Apnea (OSA) are due ~ Apr 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT07635563: Phase 2 trial, sponsor Incannex Healthcare Ltd, drug IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide. Primary completion date 2027-04 (estimated).”